SI2118098T1 - Polimorfne oblike makrocikličnega inhibitorja HCV - Google Patents

Polimorfne oblike makrocikličnega inhibitorja HCV

Info

Publication number: SI2118098T1
Authority: SI; Slovenia
Prior art keywords: hcv; polymorphic forms; macrocyclic inhibitor; macrocyclic; inhibitor
Prior art date: 2007-02-01

Application number

SI200831337T

Other languages

English (en)

Inventor

Sigrid Carl Maria Stokbroekx

Carina Leys

Kelly Ann Swinney

Stijn Wuyts

Andras Horvath

Original Assignee

Janssen R&D Ireland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-01

Filing date

2008-02-01

Publication date

2015-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229348&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2118098(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-01 Application filed by Janssen R&D Ireland filed Critical Janssen R&D Ireland

2015-01-30 Publication of SI2118098T1 publication Critical patent/SI2118098T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SI200831337T 2007-02-01 2008-02-01 Polimorfne oblike makrocikličnega inhibitorja HCV SI2118098T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP07101563		2007-02-01
EP08708575.9A EP2118098B1 (en)	2007-02-01	2008-02-01	Polymorphic forms of a macrocyclic inhibitor of hcv
PCT/EP2008/051268 WO2008092954A2 (en)	2007-02-01	2008-02-01	Polymorphic forms of a macrocyclic inhibitor of hcv

Publications (1)

Publication Number	Publication Date
SI2118098T1 true SI2118098T1 (sl)	2015-01-30

Family

ID=38229348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200831337T SI2118098T1 (sl)	2007-02-01	2008-02-01	Polimorfne oblike makrocikličnega inhibitorja HCV

Country Status (25)

Country	Link
US (1)	US8143402B2 (sl)
EP (1)	EP2118098B1 (sl)
JP (1)	JP5523110B2 (sl)
KR (1)	KR101580226B1 (sl)
CN (3)	CN101589040A (sl)
AR (2)	AR065136A1 (sl)
AU (1)	AU2008209696B2 (sl)
BR (1)	BRPI0806945A2 (sl)
CA (1)	CA2677170C (sl)
CL (1)	CL2008000321A1 (sl)
CY (1)	CY1116339T1 (sl)
DK (1)	DK2118098T3 (sl)
ES (1)	ES2524784T3 (sl)
HK (1)	HK1205125A1 (sl)
HR (1)	HRP20141137T1 (sl)
IL (1)	IL199215A (sl)
MX (1)	MX2009008275A (sl)
NZ (1)	NZ577568A (sl)
PL (1)	PL2118098T3 (sl)
PT (1)	PT2118098E (sl)
RU (1)	RU2533830C2 (sl)
SI (1)	SI2118098T1 (sl)
TW (1)	TWI423968B (sl)
WO (1)	WO2008092954A2 (sl)
ZA (1)	ZA200905377B (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY140680A (en)	2002-05-20	2010-01-15	Bristol Myers Squibb Co	Hepatitis c virus inhibitors
PE20070211A1 (es)	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8207341B2 (en)	2008-09-04	2012-06-26	Bristol-Myers Squibb Company	Process or synthesizing substituted isoquinolines
UY32099A (es)	2008-09-11	2010-04-30	Enanta Pharm Inc	Inhibidores macrocíclicos de serina proteasas de hepatitis c
CA2753667C (en) *	2009-02-27	2015-11-17	Ortho-Mcneil-Janssen Pharmaceuticals, Inc.	Amorphous salt of a macrocyclic inhibitor of hcv
TW201040181A (en)	2009-04-08	2010-11-16	Idenix Pharmaceuticals Inc	Macrocyclic serine protease inhibitors
CA2769652A1 (en)	2009-08-05	2011-02-10	Idenix Pharmaceuticals, Inc.	Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
BR112012018897A2 (pt)	2010-01-27	2017-10-03	Ab Pharma Ltd	Compostos poli-heterocíclicos altamente potentes como inibidores de hcv
CN103380132B (zh)	2010-12-30	2016-08-31	益安药业	菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
CA2822556A1 (en)	2010-12-30	2012-07-05	Enanta Pharmaceuticals, Inc	Macrocyclic hepatitis c serine protease inhibitors
TW201309690A (zh)	2011-02-10	2013-03-01	Idenix Pharmaceuticals Inc	巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
CN103501608A (zh) *	2011-05-04	2014-01-08	默沙东公司	药用物质、药物组合物和制备它们的方法
US8957203B2 (en)	2011-05-05	2015-02-17	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
US10201584B1 (en)	2011-05-17	2019-02-12	Abbvie Inc.	Compositions and methods for treating HCV
US8691757B2 (en)	2011-06-15	2014-04-08	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
WO2012171332A1 (zh)	2011-06-16	2012-12-20	爱博新药研发(上海)有限公司	抑制丙型肝炎病毒的大环状杂环化合物及其制备和应用
PH12014500585B1 (en) *	2011-09-16	2018-09-07	Sanofi Sa	Aniline derivatives, their preparation and their therapeutic application
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
EA201490837A1 (ru)	2011-10-21	2014-11-28	Эббви Инк.	Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон
AU2013201532B2 (en)	2011-10-21	2014-10-02	Abbvie Ireland Unlimited Company	Methods for treating HCV
SI2909205T1 (sl)	2012-10-19	2017-02-28	Bristol-Myers Squibb Company	9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
WO2014070964A1 (en)	2012-11-02	2014-05-08	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9643999B2 (en)	2012-11-02	2017-05-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
EP2914598B1 (en)	2012-11-02	2017-10-18	Bristol-Myers Squibb Company	Hepatitis c virus inhibitors
US9409943B2 (en)	2012-11-05	2016-08-09	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
JP6342922B2 (ja)	2013-03-07	2018-06-13	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	Ｃ型肝炎ウイルス阻害剤
EP3089757A1 (en)	2014-01-03	2016-11-09	AbbVie Inc.	Solid antiviral dosage forms
WO2015109925A1 (zh) *	2014-01-21	2015-07-30	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
WO2015180253A1 (zh) *	2014-05-29	2015-12-03	杭州普晒医药科技有限公司	丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
CZ2015220A3 (cs) *	2015-03-27	2016-10-05	Zentiva, K.S.	Amorfní sůl makrocyklického inhibitoru viru hepatitidy C
WO2016177625A1 (en)	2015-05-04	2016-11-10	Sandoz Ag	Amorphous simeprevir potassium
CN105503851B (zh) *	2015-12-09	2017-06-23	重庆润生科技有限公司	一种烯基噻唑衍生物的制备方法
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1771050A (zh) *	2003-02-07	2006-05-10	益安药业	丙型肝炎丝氨酸蛋白酶的大环抑制剂
BRPI0414814A (pt) *	2003-09-26	2006-11-14	Schering Corp	inibidores macrocìclicos de protease de serina ns3 de vìrus de hepatite c
RS20110578A3 (en) *	2003-10-14	2016-02-29	F. Hoffmann-La Roche Ltd	MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
DE602005017582D1 (en) *	2004-01-30	2009-12-24	Medivir Ab	Hcv ns-3 serine protease inhibitoren
PE20070211A1 (es) *	2005-07-29	2007-05-12	Medivir Ab	Compuestos macrociclicos como inhibidores del virus de hepatitis c

2008
- 2008-02-01 SI SI200831337T patent/SI2118098T1/sl unknown
- 2008-02-01 AR ARP080100427A patent/AR065136A1/es not_active Application Discontinuation
- 2008-02-01 JP JP2009547702A patent/JP5523110B2/ja not_active Expired - Fee Related
- 2008-02-01 PL PL08708575T patent/PL2118098T3/pl unknown
- 2008-02-01 CL CL200800321A patent/CL2008000321A1/es unknown
- 2008-02-01 EP EP08708575.9A patent/EP2118098B1/en not_active Not-in-force
- 2008-02-01 CN CNA2008800030601A patent/CN101589040A/zh active Pending
- 2008-02-01 BR BRPI0806945-0A2A patent/BRPI0806945A2/pt not_active Application Discontinuation
- 2008-02-01 AU AU2008209696A patent/AU2008209696B2/en not_active Ceased
- 2008-02-01 KR KR1020097015553A patent/KR101580226B1/ko not_active Expired - Fee Related
- 2008-02-01 RU RU2009132660/04A patent/RU2533830C2/ru not_active IP Right Cessation
- 2008-02-01 WO PCT/EP2008/051268 patent/WO2008092954A2/en not_active Ceased
- 2008-02-01 CN CN201510303203.2A patent/CN105037347B/zh not_active Expired - Fee Related
- 2008-02-01 DK DK08708575.9T patent/DK2118098T3/en active
- 2008-02-01 CN CN201410412076.5A patent/CN104230918B/zh not_active Expired - Fee Related
- 2008-02-01 MX MX2009008275A patent/MX2009008275A/es active IP Right Grant
- 2008-02-01 HR HRP20141137AT patent/HRP20141137T1/hr unknown
- 2008-02-01 NZ NZ577568A patent/NZ577568A/en not_active IP Right Cessation
- 2008-02-01 PT PT87085759T patent/PT2118098E/pt unknown
- 2008-02-01 ES ES08708575.9T patent/ES2524784T3/es active Active
- 2008-02-01 CA CA2677170A patent/CA2677170C/en not_active Expired - Fee Related
- 2008-02-01 US US12/518,548 patent/US8143402B2/en not_active Expired - Fee Related
- 2008-02-01 TW TW097103909A patent/TWI423968B/zh not_active IP Right Cessation
2009
- 2009-06-07 IL IL199215A patent/IL199215A/en active IP Right Grant
- 2009-07-31 ZA ZA200905377A patent/ZA200905377B/xx unknown
2014
- 2014-12-11 CY CY20141101034T patent/CY1116339T1/el unknown
2015
- 2015-06-23 HK HK15105950.0A patent/HK1205125A1/xx unknown
2017
- 2017-06-19 AR ARP170101687A patent/AR108819A2/es unknown

Also Published As

Publication number	Publication date
CA2677170C (en)	2017-04-18
HK1137438A1 (en)	2010-07-30
US20100029715A1 (en)	2010-02-04
CN105037347B (zh)	2018-06-01
JP5523110B2 (ja)	2014-06-18
KR20090115929A (ko)	2009-11-10
PL2118098T3 (pl)	2015-03-31
CY1116339T1 (el)	2017-02-08
DK2118098T3 (en)	2014-12-08
ZA200905377B (en)	2010-10-27
CA2677170A1 (en)	2008-08-07
AU2008209696A1 (en)	2008-08-07
CN105037347A (zh)	2015-11-11
IL199215A (en)	2015-10-29
RU2533830C2 (ru)	2014-11-20
EP2118098A2 (en)	2009-11-18
WO2008092954A2 (en)	2008-08-07
HRP20141137T1 (hr)	2015-01-30
WO2008092954A8 (en)	2009-12-23
RU2009132660A (ru)	2011-03-10
AR108819A2 (es)	2018-09-26
WO2008092954A3 (en)	2008-10-02
TW200846347A (en)	2008-12-01
US8143402B2 (en)	2012-03-27
AR065136A1 (es)	2009-05-20
KR101580226B1 (ko)	2015-12-24
NZ577568A (en)	2012-02-24
HK1205125A1 (en)	2015-12-11
AU2008209696B2 (en)	2013-05-09
ES2524784T3 (es)	2014-12-12
EP2118098B1 (en)	2014-09-24
TWI423968B (zh)	2014-01-21
CN104230918A (zh)	2014-12-24
CL2008000321A1 (es)	2008-08-22
PT2118098E (pt)	2014-12-09
JP2010517971A (ja)	2010-05-27
CN101589040A (zh)	2009-11-25
BRPI0806945A2 (pt)	2014-05-06
MX2009008275A (es)	2009-08-12
CN104230918B (zh)	2018-01-26

Publication	Publication Date	Title
ZA200905377B (en)	2010-10-27	Polymorphic forms of a macrocyclic inhibitor of HCV
PL2121674T3 (pl)	2010-10-29	Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV
ZA200808224B (en)	2009-05-27	Polymorphs
IL210345A0 (en)	2011-03-31	Crystalline forms of a 2 - thiazolyl - 4 - quinolinyl - oxy derivative, a potent hcv inhibitor
PT2094708E (pt)	2014-01-07	Pirrolopirazina como inibidor da cinase syk
EP1978966A4 (en)	2010-11-10	TRICYCLIC INHIBITORS OF 5-LIPOXYGENASE
ZA200902496B (en)	2010-06-30	HCV Nucleoside Inhibitor
BRPI0807087A2 (pt)	2014-06-10	Inibidores de hcv macrocíclicos substituídos de pirimidina
IL199640A0 (en)	2010-04-15	Hcv inhibiting macrocyclic phenylcarbamates
IL196706A0 (en)	2009-11-18	Crystalline forms of rapamycin analogs
EP2036894A4 (en)	2011-01-12	AURORA INHIBITOR
IL243058A0 (en)	2016-02-29	Amorphous salt of macrocyclic hcv inhibitor
IL213246A0 (en)	2011-07-31	Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
EP2123272A4 (en)	2010-04-21	ADAM INHIBITORS
GB201002676D0 (en)	2010-04-07	Inhibition of alpha synuclein toxicity
ZA200903609B (en)	2010-07-28	Motilide polymorphs
GB0623381D0 (en)	2007-01-03	Use of a compound as VEGF inhibitor
EP1983997A4 (en)	2009-06-17	CRYSTALLINE FORMS OF A FARNESYL DIBENZODIAZEPINONE
GB0619888D0 (en)	2006-11-15	New polymorphic forms of pregabalin
ZA200900740B (en)	2010-05-26	Crystalline forms of rapamycin analogs
GB0700807D0 (en)	2007-02-21	A method of printing
GB0617364D0 (en)	2006-10-11	Inflatable show junp
GB0720364D0 (en)	2007-11-28	Inhibitor